Insys Therapeutics reports dismissal of stockholder class action lawsuit Insys Therapeutics announced that the previously reported stockholder class action lawsuit that had been filed against the company and certain of its officers and directors in U.S. District Court for the District of Arizona was on February 20, voluntarily dismissed by the plaintiff and thereafter terminated by the court. No payment or consideration of any kind was made by any of the defendants in connection with the dismissal.
News For INSY From The Last 14 Days
Check below for free stories on INSY the last two weeks.
Insys Therapeutics weakness a buying opportunity, says JMP Securities JMP Securities said Insys Therapeutics (INSY) is weak on concerns that Subsys may be added to Express Scripts' (ESRX) exclusion list in 2015. The analyst does not know if it will or not be added but said the potential impact would not be material to sales or growth because the product is not included in any PBM preferred formula positions and has prior authorization requirements. The analyst would use weakness as a buying opportunity and reiterates its Outperform rating and $65 price target.